MALARIA

This early-stage trial tests a new malaria vaccine called PfSPZ-LARC2 in up to 22 healthy adults who have never had malaria. The vaccine uses live but genetically weakened malaria parasites that stop developing late in the liver, aiming to trigger a stronger immune response than …

This study tests two experimental malaria vaccines in 360 children aged 5 to 36 months in Burkina Faso, a country where malaria is common. The vaccines aim to prevent malaria caused by the Plasmodium falciparum parasite. Researchers will check how safe the vaccines are, how well …

This large-scale study tests the R21/Matrix-M vaccine to prevent malaria in 4,800 children aged 5-36 months living in Africa. The vaccine aims to protect against the most dangerous form of malaria. Researchers will measure how well it works and check for side effects over one yea…

This trial compares two new types of insecticide-treated bed nets against standard nets to see if they better prevent malaria in children aged 6 months to 10 years in central Côte d'Ivoire. About 1,650 people are taking part across multiple villages. The new nets contain either a…

This Phase 1 trial in Mali will test the safety of the PfSPZ malaria vaccine in 400 healthy pregnant women aged 18-34. Participants will receive three injections of either the vaccine or a placebo. The study will monitor both mothers and their infants for up to a year after birth…

This Phase 3 trial in Uganda tests whether giving young children monthly malaria prevention medicine (dihydroartemisinin-piperaquine) from 8 weeks to 1 or 2 years of age helps them develop stronger immunity against malaria later. 924 children are enrolled and followed until age 4…

This study tests the safety of an experimental medicine called L9LS in infants aged 1 to 12 months in Mali. It also looks at how L9LS affects the immune response to a malaria vaccine called R21/Matrix-M. The goal is to find a better way to prevent malaria in young children.

This study was designed to see if giving a single dose of an antibody called L9LS changes how well the R21/Matrix-M malaria vaccine works. It planned to enroll healthy adults and infants in Mali. However, the trial was withdrawn before any participants were enrolled, so no data w…

This study tracks how often people of all ages in two Liberian villages get malaria, and how many mosquitoes carry the parasite. Researchers will test blood samples monthly and collect mosquitoes from homes. The goal is to gather data that could help decide the best way to use a …